OncoMatch/Clinical Trials/NCT07039968
Standard Dose Versus High Dose Stereotactic Spine Radiosurgery for Metastatic Spinal Neoplasms
Is NCT07039968 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for spinal neoplasms.
The goal of this clinical trial is to learn if a higher dose of Stereotactic Spine Radiosurgery (SSRS), an advanced radiation technique, is better for treating cancer that has spread to the spine (spinal metastases). The study will also learn about the safety of using a higher dose. The main questions it aims to answer are: Does a higher radiation dose lead to fewer treatment failures (meaning the tumor growing back or causing serious side effects) one year after treatment? What are the side effects associated with the high dose compared to the standard dose? How does each radiation dose affect a patient's pain and quality of life? Researchers will randomly assign participants (like a coin toss) to one of two groups to compare the outcomes: The Standard Dose Group: Will receive a single radiation treatment of 16 Gy. The High Dose Group: Will receive a single, more powerful radiation treatment of 20 Gy. Participants in this study will: Receive a single, one-time, highly-focused radiation treatment (SSRS) to the spinal tumor. Attend regular follow-up visits at the clinic for checkups and imaging scans (like MRI). Complete questionnaires about their pain levels and quality of life during these visits.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: radiotherapy
Prior radiotherapy or radiosurgery to the index spine(s)
Lab requirements
Kidney function
Serum creatinine ≤ 2.0 mg/dL within 90 days prior registration
Cardiac function
Transmural myocardial infarction ≤ 6 months prior to registration, unstable angina or congestive heart failure requiring hospitalization ≤ 6 months prior to registration, life-threatening uncontrolled clinically significant cardiac arrhythmias [excluded]
Serum creatinine > 2.0 mg/dL within 90 days prior registration [excluded]; Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects [excluded]; Cardiac exclusion criteria as listed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify